Bank of America
ALNY icon

Bank of America’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bank of America’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-200,000
Closed -$91.2M – 7329
2025
Q3 		$91.2M Buy
+200,000
New +$81.4M 0.01% 1269
2025
Q2 		– Sell
-5,500
Closed -$1.49M – 8369
2025
Q1 		$1.49M Buy
+5,500
New +$1.41M ﹤0.01% 4937
2024
Q1 		– Sell
-900
Closed -$172K – 7700
2023
Q4 		$172K Sell
900
-25,000
-97% -$4.26M ﹤0.01% 6149
2023
Q3 		$4.59M Buy
25,900
+25,000
+2,778% +$4.77M ﹤0.01% 3487
2023
Q2 		$171K Sell
900
-36,100
-98% -$7.16M ﹤0.01% 5942
2023
Q1 		$7.41M Buy
37,000
+35,200
+1,956% +$7.4M ﹤0.01% 3121
2022
Q4 		$428K Hold
1,800
– – ﹤0.01% 5496
2022
Q3 		$360K Sell
1,800
-224,000
-99% -$42.7M ﹤0.01% 5622
2022
Q2 		$32.9M Buy
225,800
+224,000
+12,444% +$31.8M ﹤0.01% 1572
2022
Q1 		$294K Buy
+1,800
New +$274K ﹤0.01% 6207
2021
Q3 		– Sell
-39,800
Closed -$6.75M – 8077
2021
Q2 		$6.75M Buy
+39,800
New +$5.83M ﹤0.01% 3246
2020
Q2 		– Sell
-67,400
Closed -$7.34M – 6806
2020
Q1 		$7.34M Buy
67,400
+31,900
+90% +$3.68M ﹤0.01% 2315
2019
Q4 		$4.09M Buy
35,500
+3,000
+9% +$299K ﹤0.01% 3415
2019
Q3 		$2.61M Hold
32,500
– – ﹤0.01% 3813
2019
Q2 		$2.36M Hold
32,500
– – ﹤0.01% 3906
2019
Q1 		$3.04M Sell
32,500
-14,700
-31% -$1.23M ﹤0.01% 3635
2018
Q4 		$3.44M Sell
47,200
-1,000
-2% -$76.9K ﹤0.01% 3363
2018
Q3 		$4.22M Buy
48,200
+33,200
+221% +$3.34M ﹤0.01% 3349
2018
Q2 		$1.48M Buy
+15,000
New +$1.49M ﹤0.01% 4213
2017
Q4 		– Sell
-221,900
Closed -$26.1M – 7006
2017
Q3 		$26.1M Buy
+221,900
New +$18.9M ﹤0.01% 1638

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America's ALNY Position: Q1 2026 in Review

Bank of America increased its Alnylam Pharmaceuticals (ALNY) stake by 41% in Q1 2026, buying an estimated $95.9M and bringing the position to 966,912 shares worth $320M. The position accounts for 0.02% of the portfolio, ranked #544.

Bank of America first reported a position in ALNY in Q2 2013 and has held it in 52 quarters since. The position peaked at $683M in Q3 2025. 789 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Bank of America held 966,912 shares of Alnylam Pharmaceuticals worth $320M as of Q1 2026.
  • Bank of America bought 281,735 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $95.9M.
  • Alnylam Pharmaceuticals made up 0.02% of Bank of America's portfolio in Q1 2026, its #544 holding.
  • Bank of America first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Bank of America's Alnylam Pharmaceuticals position peaked at $683M in Q3 2025.
  • 789 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.